POPULARITY
Categories
What if targeting a single cellular pathway could slow aging and boost immunity? Dr. Joan Mannick, a leading voice in aging science, reveals how mTOR inhibitors may be the future of longevity therapeutics. From her early inspiration to groundbreaking clinical trials, Dr. Mannick explores the role of mTOR in aging, immune response, and antiviral immunity. Learn how selective mTOR inhibition could extend healthspan without compromising muscle mass, improve vaccine response in older adults, and unlock new possibilities in clinical longevity. Learn more about Dr. Joan Mannick: https://www.linkedin.com/in/joan-mannick-8089a614/ - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/
Methylene blue is widely marketed over the counter to the general public as well as to the natural health, health freedom, and freedom communities, often on the internet. It is flooding America. Some sellers are touting methylene blue as a “miracle” tonic that improves “cognitive function”1 and boosts energy to previously unimagined heights. Some have given live demonstrations on TV and podcasts demonstrating how the oral form hyperactivates some people within 35 minutes of the first dose — a typical stimulant drug rush — which is actually a danger signal for potentially activating them into a dangerous manic episode during future exposures or even more deadly outcomes. Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind In reality, methylene blue is a lethal neurotoxin, a poison to the brain. It has the same basic chemical composition and harmful clinical effects as the oldest and most neurotoxic “antidepressants,” the monoamine oxidase inhibitors (MAOIs). It also has similarities to the neurotoxic phenothiazine “antipsychotic” drugs, including the original Thorazine (chlorpromazine), but methylene blue is more stimulating or activating. Methylene blue is not a miraculous new discovery. It is the opposite. Created in 1876 in a lab — it is the oldest manmade chemical to be used in medicine. But in well over a century, methylene blue has never been FDA-approved for psychiatric purposes. Later, its chemical structure was modified in labs for creating many of the earliest, most neurotoxic psychiatric drugs. Methylene blue suppresses or destroys forms of the enzyme monoamine oxidase that are used by the brain for controlling or modulating four different powerful neurotransmitters — serotonin, dopamine, norepinephrine, and epinephrine. In short, by crushing monoamine oxidase, methylene blue causes overstimulation of four of the brain's major neurotransmitters, all of which profoundly impact the mind. After the FDA was created in 1906, methylene blue was grandfathered into the market by the agency as an obscure antidote for methemoglobinemia, but it must be emphasized that the FDA has never tested the safety of methylene blue for any purpose. Furthermore, the FDA, based on its adverse reporting system and scientific reports, has published serious warnings about potentially lethal adverse reactions from methylene blue, especially when combined with numerous other drugs.2 The first MAOIs used as depressants were derived from methylene blue, and they turned out to be so toxic that the first two were quickly taken off the market by the FDA. One caused lethal liver disease, and the other caused hypertensive crises. Methylene blue is known to impair liver function tests and to cause hypertensive crises. Early on, all MAOIs were removed for a while from the international list of approved drugs. Please go to this endnote in my report for a list of historical and scientific studies about the extraordinary history and the nature of methylene blue and the other MAOIs.3 Psychiatry and the psychopharmaceutical complex are so driven to impose neurotoxins upon our brains ⎯ some MAOI antidepressants remain on the market today. FDA Full Prescribing Information for the existing MAOI antidepressants, readily available online,4 provides quick access to the kinds of adverse effects caused by methylene blue. These FDA documents also provide lists of the foods and of some of the many, many drugs you cannot take with MAOIs, like methylene blue, without risking death from serotonin syndrome or a hypertensive crisis. Meanwhile, all of America is being made a market for the original mother of them all, methylene blue, without requiring a prescription, with bizarrely distorted claims, and with unlimited supplies handed out as easily as a new caffeinated soda. All of the three approved MAOIs, as well as methylene blue, carry repeated warnings at the FDA and in the scientific community about causing the two potentially crippling and lethal outcomes, serotonin syndrome and malignant hypertension (see below). These potentially lethal outcomes, as with all MAOIs, become much more serious and higher risk when methylene blue is taken with certain foods such as cheese and bananas, or literally with so many other drugs that it is impossible to memorize them or to keep track of them. Here is one version of a short summary of the long list of dangerous interactions between MAOIs, including methylene blue, and other drugs and foods, taken from Goodman and Gilman's The Pharmacological Basis of Therapeutics (2018, p. 274): Monoamine Oxidase Inhibitors Serotonin syndrome is the most serious drug interaction for the MAOIs (see Adverse Effects). The most common cause of serotonin syndrome in patients taking MAOIs is the accidental coadministration of a SHT reuptake-inhibiting antidepressant or tryptophan. Other serious drug interactions include those with meperidine and tramadol. MAOIs also interact with sympathomimetics such as pseudoephedrine, phenylephrine, oxymetazoline, phenylpropanolamine, and amphetamine; these are commonly found in cold and allergy medication and diet aids and should be avoided by patients taking MAOIs. Likewise, patients on MAOIs must avoid foods containing high levels of tyramine: soy products, dried meats and sausages, dried fruits, home-brewed and tap beers, red wine, pickled or fermented foods, and aged cheeses. I am presenting this detailed summary in the hope of gaining the immediate attention of people and businesses who are promoting methylene blue and anyone who is unfortunately taking it. Please share this summary or the entire document as widely as possible and with proper attribution. An extensive article follows, detailing my professional experience in the arena of psychopharmacology. It includes a lengthy scientific analysis with more than two dozen endnotes containing an even greater number of scientific citations. Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind End Notes 1 All stimulants from caffeine to Ritalin (methylphenidate) and on to methamphetamine and cocaine, and including MAOIs, can produce subjective feelings of improved concentration or memory, and some short-term studies show a brief improvement. This is caused by obsessive-compulsive mental focusing and is driven by a narrowing of general awareness and judgment. No FDA-approved stimulants, for example, have been proven to help cognition or academic performance, and all harm the brain long-term. Here is a study that is negligent in its claims and its lack of warnings about methylene blue that may have encouraged the current epidemic use: https://psychiatryonline.org/doi/full/10.1176/appi.pn.2016.pp8a5 I have researched these issues in multiple scientific papers and books, including Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Psychopharmaceutical Complex, second edition (2008). For an easily accessible, comprehensive look at stimulant drug effects, also see my free resource center on children and stimulant medications: https://breggin.com/Childrens-Resources-Center 2 Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications | FDA and FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and Drug Safety Podcasts > FDA Drug Safety Podcast for Healthcare Professionals: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications (methylthioninium chloride) and serotonergic psychiatric medications | FDA and much more comprehensive coverage of methylene blue adverse effects with special warnings for professionals can be found at Methylene Blue Monograph for Professionals – Drugs.com 3 Half_a_century_of_antidepressant_drugs_-20151101-21548-vmvosk-libre.pdf. Also see Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed and Methylene Blue in the Treatment of Neuropsychiatric Disorders – PubMed; and Iproniazid | Antidepressant, Monoamine Oxidase Inhibitor & Mental Health | Britannica; Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed; Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today – PubMed. These cover the fascinating history of MAOIs and Methylene Blue. 4 The currently approved MAOI antidepressants are phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldpryl, Emsam, Zelapar)), and isocarboxazid (Marplan). ______ Learn more about Dr. Peter Breggin's work: https://breggin.com/ See more from Dr. Breggin's long history of being a reformer in psychiatry: https://breggin.com/Psychiatry-as-an-Instrument-of-Social-and-Political-Control Psychiatric Drug Withdrawal, the how-to manual @ https://breggin.com/a-guide-for-prescribers-therapists-patients-and-their-families/ Get a copy of Dr. Breggin's latest book: WHO ARE THE “THEY” - THESE GLOBAL PREDATORS? WHAT ARE THEIR MOTIVES AND THEIR PLANS FOR US? HOW CAN WE DEFEND AGAINST THEM? Covid-19 and the Global Predators: We are the Prey Get a copy: https://www.wearetheprey.com/ “No other book so comprehensively covers the details of COVID-19 criminal conduct as well as its origins in a network of global predators seeking wealth and power at the expense of human freedom and prosperity, under cover of false public health policies.” ~ Robert F Kennedy, Jr Author of #1 bestseller The Real Anthony Fauci and Founder, Chairman and Chief Legal Counsel for Children's Health Defense.
Graph Therapeutics combines AI-driven perturbation modeling with multi-omics data to develop targeted therapies for patients with complex immune-mediated diseases who currently lack effective treatment options.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/psychiatric-therapeutics-in-a-digital-world-10096SummaryIn this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Lisa Harding delve into the digital world and breakdown its effects on mental health—both positive and negative. By the end of the episode, learners will have a better understanding of the relationship between screen time, social media, and attention, including clinical pearls for how to harness prescription technology to enhance patient outcomes in ADHD and depression.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Examine the relationship between social media and attentionIncorporate FDA-authorized digital therapeutics into ADHD and depression management plans based on current clinical evidenceThis activity is accredited for CME/CE CreditThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is not commercially supported.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO of Kither Biotech. Kither is a Phase I, soon to be Phase II, Italian biotech focused on respiratory diseases such as cystic fibrosis. This episode explores how emerging biotech strategies are advancing treatments for respiratory diseases like cystic fibrosis, with a focus on targeted drug delivery, clinical trial progression, and the evolving biotech landscape in Europe. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
Today we're heading across the Atlantic to speak to Dr. James Field, CEO of London-based LabGenius Therapeutics.LabGenius has a really exciting mission. James and his team of 60 scientists and engineers believe in the powerful combination of human and artificial intelligence, and are pioneering an ML-driven protein engineering platform - EVA - that can design and execute experiments for the development of next-gen antibodies, including complex multispecifics.LabGenius has already raised over $75m in venture capital and built R&D deals with some major pharma and biotech players. After founding the company in 2012, James was named in Forbes' ‘30 Under 30' list for science and healthcare, and even won Innovator of the Year award from the UK's Biotech & Biological Sciences Research Council. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez
In this piece we discuss perioperative medicine with Alana Flexman, an anaesthetist and researcher from Vancouver, Canada, and Maryanne Balkin, an anaesthetist and law graduate from Melbourne, Australia. We explore our guests' career journeys, and gender and equity issues, including unconscious bias and bullying, harassment, and discrimination, in the workplace. Finally we talk about the craziness and joy of continued learning and enquiry. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guests, Dr Alana Flexman, Clinical Associate Professor, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, and St. Paul's Hospital/Providence Health Care, Vancouver, Canada, and Dr Maryanne Balkin, Consultant Anaesthetist, Alfred Health, Melbourne, Australia.
Daniel Locke, M.S., is a dedicated healthcare professional and entrepreneur based in Jacksonville, Florida. He earned his Master of Science in Medical Cannabis Science and Therapeutics from the University of Maryland's School of Pharmacy in May 2024. This advanced education has equipped him with a comprehensive understanding of cannabis pharmacology, chemistry, and clinical applications.In 2017, Daniel founded Compassionate Alternative Care, a veteran-owned medical cannabis consultation firm. The organization is committed to providing personalized guidance and support to patients seeking alternative treatments. Under his leadership, the firm has educated patients on various aspects of medical cannabis, including its chemistry, drug delivery methods, and state and federal regulations. His efforts have positioned Compassionate Alternative Care as a premier practice in North Florida, supporting more than 3,000 patients.Before his work in medical cannabis, Daniel served as a Search and Rescue Swimmer in the United States Navy, demonstrating his commitment to service and helping others. He also founded Locke Roofing Company, where he managed projects, identified business opportunities, and led a team to complete large-scale roofing projects.Daniel's dedication to community service is evident through his role as Purchasing Director and Fundraising Manager for Habitat for Humanity in Jacksonville. In this capacity, he developed budgets for 200 houses annually, managed purchasing operations, hired subcontractors, and secured significant contributions from manufacturers.Throughout his diverse career, Daniel has been recognized for his entrepreneurial spirit, leadership, and advocacy for social justice. He continues to be a catalyst in the cannabis industry, striving to educate patients and healthcare professionals about the benefits and applications of medical cannabis.
We're online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.
What if fat loss could be achieved without impacting metabolism? Recorded live at AIS 2025, Dr. Grant Stevens speaks with Alon Bloomenfeld, Executive Chair of Raziel Therapeutics, about a new class of injectable fat reduction—one that works locally, not systemically. Unlike semaglutide or other metabolic treatments, this lipophilic compound directly destroys fat cells at the site of injection, offering a highly targeted, non-surgical solution for body contouring. With FDA Phase III trials underway, Bloomenfeld shares what sets this breakthrough apart.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/
In the final part of this series, Joseph Parambil, MD, walks us through the approach of managing pulmonary hypertension, reviews the pathophysiology and digs into the mechanisms and the differences in the medications. Intro 0:12 In this episode 0:17 Interview with Joseph Parambil, MD 2:53 Reviewing and clarifying pathophysiology prior to initiating therapeutics 4:13 Evaluating patients in terms of their functional status and how does that play a role in initiating therapies 4:25 Vasoreactivity testing 10:21 The categories of medications 14:40 Endothelin receptor antagonists 37:07 TGF pathway 42:13 Scleroderma patient and treatment 50:19 Do patients get a repeat right-heart catheterization? 55:51 What about the TGF-beta? 56:55 Thank you, Dr. Parambil 58:34 Thanks for listening 59:17 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Disclosures: Brown and Parambil report no relevant financial disclosures. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic's Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine.
In this episode, Kevin M. Zinchuk, PharmD, CCRP, Denise Scarpelli, PharmD, MBA, and Jill Blind, PharmD, CCRP, give you a sneak peek into the upcoming Advanced Therapeutics Summit at the 2025 Pharmacy Futures Meeting. Tune in as we highlight key topics—from patient access and financial impact to operational strategies and interdepartmental collaboration—that will equip pharmacy leaders with practical tools to navigate this evolving landscape. Don't miss this preview of one of the most anticipated events of the conference! The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
In this episode of The Red Light Report, Dr. Mike Belkowski returns fresh from the Health Optimization Summit in Austin, Texas, where he reconnected with the vibrant biohacking community. While the event buzz was exciting, Dr. Mike dives right back into what he does best: breaking down cutting-edge research in mitochondrial health and red light therapy. Key Topics Covered: 1. The Mitochondria–Gut Microbiota–Cardiovascular Axis Dr. Mike reviews a pre-release study that uncovers the two-way relationship between our gut microbes and mitochondrial function. Disruptions here may fuel inflammation and oxidative stress, leading to cardiovascular disease. The fix? Support both systems with red light therapy, methylene blue, probiotics, and lifestyle upgrades. 2. Phytochemicals & Gut Health A second study emphasizes how plant compounds like polyphenols and phytochemicals can rebalance gut flora and reduce inflammation. The takeaway: what we eat shapes our gut — and therefore our aging process and mitochondrial efficiency. 3. Red Light Therapy for the Gut-Brain Axis Dr. Mike explores three new studies showing that red and near-infrared light applied to the abdomen can: • Boost beneficial gut bacteria • Improve cognitive and motor function (even in Parkinson's patients) • Decrease harmful microbes He shares exact dosages and frequencies from the research — including exciting applications of pulsed frequencies (e.g., 700Hz) and intranasal photobiomodulation. 4. BioLight's New Methylene Blue Blend – BioBlue Mike reintroduces his company's enhanced methylene blue product, BioBlue, which includes NMN, colloidal gold/silver, and fulvic acid for boosted mitochondrial absorption and synergy with red light therapy. 5. Mitochondrial Inheritance Bombshell To close the episode, Dr. Mike unpacks a groundbreaking (but still early-stage) study suggesting that mitochondria might not be passed down exclusively from mothers. Some animal studies hint that paternal mitochondrial inheritance might occasionally occur — a potential paradigm shift in mitochondrial genetics. If you found the information in today's episode particularly interesting and/or compelling, please share it with a family member, friend, colleague and/or anyone that you think could benefit and be illuminated by this knowledge. Sharing is caring :) As always, light up your health! - Key Points: 00:00 – Event Recap: Health Optimization Summit 02:14 – Mitochondria-Gut-CVD Crosstalk (Pre-release study) 08:52 – Therapeutics for Gut and Mitochondria 10:41 – Methylene Blue: Brain + Mitochondria 13:42 – Red Light Target Zones for General Health 18:33 – Diet + Phytochemicals for Gut and Aging 22:27 – Red Light Therapy + Gut Microbiome (3 Studies) 32:00 – Pulse Frequencies + Optimization Tips 36:42 – Personalization + Gut/Mitochondria Tie-in 39:14 – Mitochondria Inheritance: Paternal Surprise - Articles referenced in episode: The mitochondria-gut microbiota crosstalk – A novel frontier in cardiovascular diseases Promotion of Healthy Aging Through the Nexus of Gut Microbiota and Dietary Phytochemicals Photobiomodulation of gut microbiota with low-level laser therapy: a light for treating neuroinflammation Research progress on paternal mitochondrial inheritance: An overview - Upcoming BioLight Events: Biohacking Conference - May 28 - 30 (Austin, TX) Returning to Nature (Quantum Health Retreat), June 26 - 27 (Franklin, TN) - Save 25% when you Subscribe & Save to a BioBundle! For a BioBundle, you choose:1.) Any one BioBlue supplement(BioBlue, BioBlue (SR), BioBlue Leuco, BioBlue Calm, BioBlue Capsules or BioBlue Leuco Capsules)2.) Any one BioC60 supplement(Regular or Concentrated) The BioBundle automatically saves you 15% on both of the supplements you choose.You save an additional 10% by choosing to Subscribe & Save to that BioBundle.The 25% savings is passed along for every monthly delivery of your BioBundle!No discount code necessary! Click here to check out The BioBundle - Dr. Mike's #1 recommendations: Water products: Water & Wellness Grounding products: Earthing.com EMF-mitigating products: Somavedic Blue light-blocking glasses: Ra Optics - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn BioLight: Website Instagram YouTube Facebook
Daniel Getts, the CEO and Founder of Myeloid Therapeutics, is focused on the role of myeloid cells in the immune response to solid tumors. These cells are the first responders in the immune system and play a crucial role in bridging the innate and adaptive immune response. The Myeloid Therapeutics' mRNA technology activates myeloid cells in tumors, making the tumor microenvironment hot and attracting other immune cells to fight the cancer. Daniel explains, "The ability to harness our immune systems has revolutionized how we treat cancer. Unfortunately, we still have a long way to go, and if you think about some of the worst of the worst cancers, such as pancreatic cancer, liver cancer, and so on, immunotherapy has still not gotten us to a place where we can solve this. It's our mission at Myeloid Therapeutics to overcome these challenges. We've uncovered a lot of really interesting things about these cancers in the last 20 years, and we've been harnessing that knowledge." "Myeloid cells are at the heart of the immune system. They're the first responders. So, if you have an infection or bump your knee, these cells are immediately called to the site to wall off and prevent any more damage. However, they also serve as the bridge to adaptive immunity, the T cells and the B cells, which are also important for integrating an immune response. In the context of COVID vaccines, we talk about antibodies and T cells, it's the myeloid cells that are essential. In the context of what we've been learning, immunotherapy, up until recently, had been very focused on T cells and how to short-circuit the whole system just by using or activating those cells to kill cancer. And what we're starting to learn is to harness the full capability of our own immune systems, you've got to go back to the start. You've got to harness the myeloid compartment so you can orchestrate all immune elements to kill cancer." #MyeloidTherapeutics #MyeloidCells #ImmuneSystem #SolidTumors #Cancer #ImmuneResponse #Oncology #TumorMicroenvironment myeloidtx.com Listen to the podcast here
Daniel Getts, the CEO and Founder of Myeloid Therapeutics is focused on the role of myeloid cells in the immune response to solid tumors. These cells are the first responders in the immune system and play a crucial role in bridging the innate and adaptive immune response. The Myeloid Therapeutics' mRNA technology activates myeloid cells in tumors, making the tumor microenvironment hot and attracting other immune cells to fight the cancer. Daniel explains, "The ability to harness our immune systems has revolutionized how we treat cancer. Unfortunately, we still have a long way to go, and if you think about some of the worst of the worst cancers, such as pancreatic cancer, liver cancer, and so on, immunotherapy has still not gotten us to a place where we can solve this. It's our mission at Myeloid Therapeutics to overcome these challenges. We've uncovered a lot of really interesting things about these cancers in the last 20 years, and we've been harnessing that knowledge." "Myeloid cells are at the heart of the immune system. They're the first responders. So, if you have an infection or bump your knee, these cells are immediately called to the site to wall off and prevent any more damage. However, they also serve as the bridge to adaptive immunity, the T cells and the B cells, which are also important for integrating an immune response. In the context of COVID vaccines, we talk about antibodies and T cells, it's the myeloid cells that are essential. In the context of what we've been learning, immunotherapy, up until recently, had been very focused on T cells and how to short-circuit the whole system just by using or activating those cells to kill cancer. And what we're starting to learn is to harness the full capability of our own immune systems, you've got to go back to the start. You've got to harness the myeloid compartment so you can orchestrate all immune elements to kill cancer." #MyeloidTherapeutics #MyeloidCells #ImmuneSystem #SolidTumors #Cancer #ImmuneResponse #Oncology #TumorMicroenvironment myeloidtx.com Download the transcript here
Alissa Coram and Ken Shreve analyze Wednesday's market action and discuss key stocks to watch on Stock Market Today.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.Disclosure information is available at the beginning of the video presentation.
In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Graham Hatfull, a Professor of Biological Sciences at the University of Pittsburgh. Dr Hatfull joins Dr Saag to discuss Bacteriophages for the treatment of antimicrobial-resistant (AMR) bacterial infections. Dr Hatfull provides an overview of the types of bacteriophages and how they can be used to treat antimicrobial-resistant bacteria. Dr Hatfull and Dr Saag discuss the challenges of treating bacterial infections with phages given the diversity and complexity of the different types of bacteria and bringing phage treatments to scale. Finally, they discuss what research is needed to overcome the challenges of phage treatment and look to the future where technology enables synthetically produced phages to provide targeted therapy to antimicrobial resistant bacteria.0:00 – Introduction1:05 – Overview of bacteriophages and Dr Hatfull's interest in phage research2:46 – How phages can be used clinically for antimicrobial-resistant bacteria4:34 – Differences between the 2 types of phages: lytic phages and temperate phages6:01 – How phages are used to target specific types of bacteria9:37 – The challenge of phage treatment matching and natural CRISPR processes within bacteria15:16 – Understanding the phage genome diversity 18:59 – Discussion of therapeutic uses of phages28:32 – Prospect of phages for future treatments including synthetic phagesResources: Harnessing the Power of Bacteriophages with Dr Robert Schooley:YouTube: https://youtu.be/_BUpDRNhMsQApple Podcasts: https://podcasts.apple.com/us/podcast/episode-10-harnessing-the-power-of-bacteriophages/id1713226144?i=1000647215580 Exploring Bacteriophage Therapy for Drug-Resistant Bacterial Infections Robert T. Schooley, MD: https://www.iasusa.org/wp-content/uploads/2023/03/31-1-23.pdf The inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics: https://www.iasusa.org/bacteriophage-conference/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...
This week on The Genetics Podcast, Patrick is joined by Salvador Rico, Chief Medical Officer at Encoded Therapeutics. They discuss Salvador's journey into drug development, his work on gene therapy for X-linked myotubular myopathy, and fundamental challenges and exciting advances in the genetics field.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Salvador and how he became involved in drug development11:01 Frustrations and rewards of the genetics field13:59 Salvador's study on gene therapy for patients with X-linked myotubular myopathy (XLMTM)19:46 Risk of liver issues in gene therapy trials and attempts to mitigate them24:22 Encoded Therapeutics‘ approach to drug discovery and what motivated Salvador to join the team27:22 Steps towards therapeutic targeting of gene regulatory elements 30:04 Advantages of different methods for drug delivery 32:31 DNA- versus RNA-based therapy 34:56 Insights from approaches in other fields, including psychiatry36:35 Considerations for using natural history studies40:32 Expectations and goals for Encoded Therapeutics' current and upcoming studies43:17 Closing remarksFind out moreEncoded Therapeutics (https://encoded.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
Dr. Janine Sengstack is the Chief Scientific Officer and co-founder of Junevity, a company created in 2023 with the mission of extending health span and lifespan through what they term "Cell Reset therapeutics." The company recently secured $10 million in seed funding.In this episode, Chris and Janine explore the innovative platform Janine developed during her PhD work in Hao Li's lab at UCSF, which now forms the foundation of Junevity's therapeutic approach. They discuss how the company uses computational and experimental methods to identify transcription factors that can "reset" cells from a diseased, aged state back to a healthy state while maintaining cell identity. Janine explains how Junevity is developing siRNA therapeutics targeting these transcription factors to treat age-related diseases, with a focus on metabolic conditions and other disorders that impact longevity.The Finer Details:The development of the Reset platform during Janine's PhD work and its evolution into Junevity's therapeutic approachHow transcription factors act as "managers" in cells, regulating many other genesUsing AI and machine learning to identify the right transcription factors to target based on disease and tissue-specific dataThe validation process for siRNA therapeutic candidates in cell and animal modelsJunevity's focus on diseases with large-scale transcriptional dysregulation, including type 2 diabetes, obesity, muscle wasting diseases, and osteoarthritisThe advantages of siRNA as a therapeutic modality for targeting traditionally "undruggable" transcription factorsJunevity's business strategy and timeline, with clinical trials potentially beginning in 2026Quotes:"We tackled this high risk, high reward PhD project: we were inspired by the Yamanaka factors to say, 'Okay, let's find brand new transcription factors that we can target to take cells from a diseased, old state and bring them back to a healthy state while keeping them the same cell type, never turning them into a stem cell.'""Transcription factors: I like to think of them as managers in the cell.""We think the advent of modern AI and machine learning tools to better analyze what they regulate, plus siRNA as a really well-proven therapeutic modality, really unlocks the ability to target transcription factors and really make powerful therapeutics with them.""We're thinking about using transcriptional regulation as a way to come up with novel therapeutics to treat diseases that have a big impact on people's health span and lifespan.""We want to advance our programs towards development candidates, which basically means the drug entity, and move them forward towards clinical development as fast as possible.""I would love if we had multiple siRNA drugs on the market, ideally, or in late stages of development for a wide range of longevity-related diseases... We think that there's really huge potential here for making a big impact on a lot of different really complicated diseases."Linkshttps://www.junevity.com
What if your skin could do more than protect you? In this thought-provoking episode of The Technology of Beauty, Dr. Grant Stevens sits down with Ryan Beal, the CEO of Dyve Biosciences, to explore how transcutaneous drug delivery is poised to reshape both the aesthetics industry and the field of oncology. With Dyve's pioneering platform, molecules once limited to injections or oral delivery are now being driven through the skin — offering a powerful new frontier in treatment possibilities.Ryan walks us through Dyve's surprising evolution from skincare applications and elite athletic performance enhancement to its most ambitious moonshots: noninvasive fat reduction and improving chemotherapy effectiveness through targeted pH modulation.This episode also takes a personal turn, as Ryan opens up about his recent battle with cancer—a diagnosis that came just months after speaking about oncology research on a previous episode. Now a survivor, Ryan shares how his company's technology played a direct role in his treatment, potentially boosting the efficacy of his own chemotherapy regimen. It's a powerful testament to the impact of innovation when professional purpose and personal experience collide.From fat-melting topicals to transdermal neurotoxins and tumor microenvironment alkalinization, Ryan Beal offers an inspiring look at how Dyve Biosciences is transforming medicine one molecule—and one patient—at a time. Don't miss this candid, cutting-edge conversation about the future of drug delivery and the deeply human stories behind biotech breakthroughs on the latest episode of The Technology of Beauty.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/
Antimicrobial resistance has become one of healthcare's biggest challenges, and in the fight against AMR getting the right drug, the right dose, right indication and the right route is everything. In this episode, we're exploring the critical role clinical pharmacists play in antimicrobial stewardship (AMS). Join Nonks, the latest microbe messenger to take the mic, as she talks to seasoned clinical pharmacist Ama Annor.About our Guest: Ama Sakoa Annor, is a committed and proactive pharmacist who is trained in comprehensive pharmaceutical care for paediatric patients. She holds an MSc (Med) in Clinical Pharmacy and a DPharm Candidate with six publications.She is currently working at Dr George Mukhari Academic Hospital as a ward pharmacist, stationed in the paediatric medical and surgical departments. She is a member of the hospital's Pharmacy and Therapeutics, AMS, ADR Committee and other sub-committees.She is also affiliated as a mentor with the Clinical Pharmacy Division of the School of Pharmacy of the Sefako Makgatho Health Sciences University. She has a passion for rational antimicrobial use and is privileged to be one of the mentees in the Ohio State University/Nationwide Children's Hospital - South Africa Train-the-Trainer program in the Neonatal Antimicrobial Stewardship Program in 2019. Two of the end products are the recent publications: “Prospective antimicrobial stewardship interventions by multidisciplinary teams to reduce neonatal antibiotic use in South Africa: the Neonatal Antimicrobial Stewardship (NeoAMS) study”. International Journal of Infectious Diseases 2024-06 | Journal article. https://doi.org/10.1016/j.ijid.2024.107158“Defining and responding to the contextual drivers for implementation of antimicrobial stewardship in 14 neonatal units in South Africa”; JAC-Antimicrobial Resistance 2025 Vol. 7 Issue 1 https://doi.org/10.1093/jacamr/dlae222Facebook: Ama Sakoa AnnorLinkedin_ama_sakoa-annorX: @ama_sakoa_annorInstagram: amasakoaAlso listen to this: Episode 6: A is for antimicrobial stewardshipWE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us:
This week your host Fred Williams and co-host Doug McBurney welcome Dr. James Oschman for his beneficial insights on the connection between our bodies, energy, information and the creation, (specifically the earth). *Welcome James Oschman, PhD: Dr. Oschman has both academic credentials and a background in alternative therapies. His degrees are in Biophysics and Biology from the University of Pittsburgh. He has worked in major research labs around the world, including Cambridge, Case-Western, the University of Copenhagen, Northwestern where he was on the faculty, and the Marine Biological Laboratory, where he was a staff scientist. His many scientific papers have been published in the world's leading journals. He's written 3 books, The Resonance Effect: How Frequency Specific Microcurrent Is Changing Medicine, Energy Medicine: The Scientific Basis and Energy Medicine in Therapeutics and Human Performance: providing a theoretical basis for exploring the physiology and biophysics of energy medicine. *The Dust of the Ground: Genesis clearly indicates a connection between our mortal bodies and the earth: Gen 2:7, “And the LORD God formed man of the dust of the ground, and breathed into his nostrils the breath of life; and man became a living soul. Gen 3:17b, “...cursed is the ground for thy sake; in sorrow shalt thou eat of it all the days of thy life…” Gen 4:11-12, “And now art thou cursed from the earth, which hath opened her mouth to receive thy brother's blood from thy hand; When thou tillest the ground, it shall not henceforth yield unto thee her strength…” *Earthing: Hear how Earthing - simply grounding yourself to the earth (especially while sleeping) can improve your health and quality of life, and help with inflammation and dozens if not hundreds of other health problems. *Bone of my Bone: Hear how the peizo-electrical effect affects and encourages skeletal health. *Magnetism, Meridians & the Placebo Effect: Ever noticed how just holding a sore spot makes it feel better? Why is that? Hear some fascinating incites on how knowledge of electromagnetism, information science and physics are beginning to teach us that an understanding of such sciences among medical doctors will improve medicine! *Mysticism, Materialism vs Biophysics: Find out how the perceived mystical aspects of energy and earth medicines are beginning to be explained in light of the biophysical and information sciences.
This week your host Fred Williams and co-host Doug McBurney welcome Dr. James Oschman for his beneficial insights on the connection between our bodies, energy, information and the creation, (specifically the earth). *Welcome James Oschman, PhD: Dr. Oschman has both academic credentials and a background in alternative therapies. His degrees are in Biophysics and Biology from the University of Pittsburgh. He has worked in major research labs around the world, including Cambridge, Case-Western, the University of Copenhagen, Northwestern where he was on the faculty, and the Marine Biological Laboratory, where he was a staff scientist. His many scientific papers have been published in the world's leading journals. He's written 3 books, The Resonance Effect: How Frequency Specific Microcurrent Is Changing Medicine, Energy Medicine: The Scientific Basis and Energy Medicine in Therapeutics and Human Performance: providing a theoretical basis for exploring the physiology and biophysics of energy medicine. *The Dust of the Ground: Genesis clearly indicates a connection between our mortal bodies and the earth: Gen 2:7, “And the LORD God formed man of the dust of the ground, and breathed into his nostrils the breath of life; and man became a living soul. Gen 3:17b, “...cursed is the ground for thy sake; in sorrow shalt thou eat of it all the days of thy life…” Gen 4:11-12, “And now art thou cursed from the earth, which hath opened her mouth to receive thy brother's blood from thy hand; When thou tillest the ground, it shall not henceforth yield unto thee her strength…” *Earthing: Hear how Earthing - simply grounding yourself to the earth (especially while sleeping) can improve your health and quality of life, and help with inflammation and dozens if not hundreds of other health problems. *Bone of my Bone: Hear how the peizo-electrical effect affects and encourages skeletal health. *Magnetism, Meridians & the Placebo Effect: Ever noticed how just holding a sore spot makes it feel better? Why is that? Hear some fascinating incites on how knowledge of electromagnetism, information science and physics are beginning to teach us that an understanding of such sciences among medical doctors will improve medicine! *Mysticism, Materialism vs Biophysics: Find out how the perceived mystical aspects of energy and earth medicines are beginning to be explained in light of the biophysical and information sciences.
We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena's AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena's XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.Subscribe to the podcast!Apple | Spotify | YouTube
From a childhood hospital bed to the founding of her own Biotech company, Ulrika Norin's journey into drug discovery has been anything but conventional. In this episode of Careers in Discovery, we speak with the founder and CEO of Serendo Therapeutics about her mission to transform treatment for autoimmune disease - starting with a breakthrough she made during her PhD. Ulrika shares how a long-standing fascination with the immune system led her to discover Endothelin A2 as a key regulator of autoimmunity, and how that science laid the foundation for Serendo. She talks openly about the leap from scientist to CEO, the pressures of leadership, and what it really means to build something from scratch. We also explore her time at Karolinska and Omnio, the importance of mentorship and networks, and why the best advice is to follow your gut - even if the path isn't linear. If you're curious about what it takes to spin out an idea into a company, balance passion with pressure, and lead with authenticity, this is one for you.
Synopsis: In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mission-driven leadership. He dives into Zevra's recent therapeutic milestones, regulatory strategies, and the importance of reflection in high-stakes environments. This conversation offers powerful takeaways for anyone navigating biotech leadership, board management, or rare disease innovation. Biography: Neil F. McFarlane took the reins as President and CEO of Zevra Therapeutics, a commercial-stage rare disease therapeutics company, in October 2023, bringing with him a wealth of experience in the biopharma industry and specific expertise in neurological and rare diseases. Before joining Zevra, he served on the board of Collegium Pharmaceutical Inc. from 2022 to 2024 and was the CEO of Adamas Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for neurological diseases, from 2019 until its acquisition by Supernus Pharmaceuticals in 2021. Prior to Adamas, Mr. McFarlane was Chief Operating Officer at Retrophin, Inc. (now Travere Therapeutics, Inc.), from 2016 to 2019, where he managed day-to-day operations. He also held roles of increasing responsibility at UCB, Inc., Genzyme Corporation (now Sanofi), and Sangstat Medical Corporation, which was acquired by Genzyme.
What if optimizing your fitness and losing weight came down to peptides? In episode 1133 of Mark Bell's Power Project Podcast, Mark Bell, Nsima Inyang, and Justin Kirkland discuss how GLP-1 peptides are transforming fitness and health. Justin explains, “It's not just about the weight loss—it's about using these compounds as tools for long-term lifestyle changes.”Learn how GLP-1 curbs cravings, supports better eating habits, and the science behind delivery methods like advanced coatings for oral absorption versus injectables. They also dive into maintaining muscle while shedding fat with strategies like resistance training and mindful nutrition.Packed with insights on peptide innovation and safe usage, this episode is a must-watch for anyone dedicated to health, fitness, and personal growth. Don't miss the conversation on using peptides to unlock better results while tackling challenges like muscle mass loss and dosage management!Special perks for our listeners below!
Stocks jumping to start the week, as investors hope President Trump may be softening his stance on tariffs. If you can believe the bounce, and the sectors seeing the biggest gains. Plus One pharma company looking to tip the scales in the weight loss drug space. What the CEO of Structure Therapeutics sees next in GLP-1 development, and how an oral pill could be the key to success.Fast Money Disclaimer
In this episode of Careers in Discovery, we're joined by Jostein Dahle, Chief Technology Officer at Blue Wave Therapeutics. Jostein has spent over two decades in radionuclide therapy, taking discoveries from the lab to patients. Now, he's developing a new treatment for glioblastoma, one of the most aggressive and challenging brain cancers, using targeted radionuclide therapy derived from Norwegian seaweed. We talk about his journey from academia to Biotech, the hard lessons of building and scaling a company, and why following the science, staying agile, and knowing when to walk away are critical in drug discovery. Jostein also shares his experience of entrepreneurship in Biotech, the challenges of funding innovative treatments, and what's next for Blue Wave as they move towards the clinic.
This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx's mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John's diverse experiences inform his approach as a leader.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to John02:01 John's background at GSK and his transition to drug discovery05:45 Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets 08:27 Genomic origins of newly-identified proteins and the process of finding them09:49 Developing the ProFoundry atlas and integrating data across assays 15:27 Different approaches to inferring protein links and association to disease17:13 Collaboration with Pfizer to find regulators in the context of obesity18:04 Developing novel antibody-drug conjugates for cancer treatment20:27 Clarifying causality in proteomic data21:59 Approaching novel targets while considering industrial and business factors25:19 John's background as a cardiologist and how that impacts his current work27:26 Tips for biotech companies looking to be noticed by pharma for collaborations30:30 Considerations for investigating new and different therapeutic modalities and techniques33:39 How John consistently reinforces the translational angle as a business leader36:24 Closing remarks and future direction for ProFound TherapeuticsFind out moreProFound Therapeutics (https://www.profoundtx.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
We love to hear from our listeners. Send us a message. The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes to his biotech leadership. We cover his transition from pharmaceutical work in Iowa to a career in biotech, the gene therapy advances Affinia is building on, the company's investment approach, its upcoming clinical trials, and much more. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
No Priors: Artificial Intelligence | Machine Learning | Technology | Startups
On this week's episode of No Priors, Sarah Guo is joined by leading members of the teams at Vevo Therapeutics and the Arc Institute – Nima Alidoust, CEO/Co-Founder at Vevo Therapeutics; Johnny Yu, CSO/Co-Founder at Vevo Therapeutics; Patrick Hsu, CEO/Co-Founder at Arc Institute; Dave Burke, CTO at Arc Institute; and Hani Goodarzi, Core Investigator at Arc Institute. Predicting protein structure (AlphaFold 3, Chai-1, Evo 2) was a big AI/biology breakthrough. The next big leap is modeling entire human cells—how they behave in disease, or how they respond to new therapeutics. The same way LLMs needed enormous text corpora to become truly powerful, Virtual Cell Models need massive, high-quality cellular datasets to train on. In this episode, the teams discuss the groundbreaking release of the Tahoe-100M single cell dataset, Arc Atlas, and how these advancements could transform drug discovery. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @Nalidoust | @IAmJohnnyYu | @PDHsh | @Davey_Burke | @Genophoria Download the Tahoe Dataset Show Notes: 0:00 Introduction 1:40 Significance of Tahoe-100M dataset 4:22 Where we are with virtual cell models and protein language models 10:26 Significance of perturbational data 17:39 Challenges and innovations in data collection 24:42 Open sourcing and community collaboration 33:51 Predictive ability and importance of virtual cell models 35:27 Drug discovery and virtual cell models 44:27 Platform vs. single hypothesis companies 46:05 Rise of Chinese biotechs 51:36 AI in drug discovery
What happens when nearly 60 years of combined biohacking expertise collide in one podcast? Peter Diamandis is a world-renowned futurist, space entrepreneur, and innovator behind groundbreaking ventures like the XPRIZE and Abundance 360. Dave sits down with Peter to combine their nearly 60 years of biohacking expertise, delivering the ultimate playbook for living longer and healthier.They dive into revolutionary AI-driven health solutions, mindset shifts that fuel vitality, and practical routines you can start today. Peter, the author of The Longevity Guidebook, shares deeply meaningful tools and tips to expand your healthspan for decades to come. What You'll Learn: • The top AI tools reshaping health and longevity • Simple daily habits that improve energy, sleep, and brain performance • Why mindset is the key to adding years to your life • The cutting-edge science of age reversal and functional health • How Peter and Dave biohack their routines for peak performance Resources: • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Peter Diamandis's New Book: https://longevityguidebook.com/home-blk-nav • Peter Diamandis's Website: https://www.diamandis.com/ • Peter Diamandis's Purpose Finder (MTP): https://purposefinder.ai/ • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Book – Smarter Not Harder: https://daveasprey.com/books • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com SPONSORS: -Omni-Biotic | Visit omnibioticlife.com/dave and use code DAVE20 for 20% off. -LMNT | Free LMNT Sample Pack with any drink mix purchase by going to drinklmnt.com/dave. Timestamps: • 00:00 Open • 00:53 Introduction to Peter Diamandis • 01:54 Peter's Longevity Journey • 03:26 Tracking Sleep and Biohacking • 05:49 The Importance of Deep Sleep • 07:22 Thinking Big and Longevity • 10:36 Russian Innovations in Sleep • 25:29 AI and Longevity • 29:01 Gene Editing and Epigenetics • 35:13 Light Therapy and Routines • 43:07 Gut Health and Endotoxins • 44:17 Exploring Conscious Pain Practices • 45:51 Hacking Hot Tubs for Health Benefits • 46:28 The Science Behind Dopamine Reset • 46:43 Introduction to Fountain Life • 48:41 Advanced Diagnostics and AI Integration • 50:29 Therapeutics and Cutting-Edge Treatments • 51:41 The Evolution of Longevity Companies • 55:30 The Future of Longevity and Healthspan • 01:01:27 The Role of AI in Health and Longevity • 01:07:31 Personal Longevity Practices and Insights • 01:16:43 Finding Your Purpose for Longevity • 01:24:01 Final Thoughts and Resources See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.